Original Article

You have full text access to this OnlineOpen article

Long-term outcome of hematuria home screening for bladder cancer in men

  1. Edward M. Messing MD1,†,*,
  2. Ralph Madeb MD1,
  3. Terry Young PhD2,
  4. Kennedy W. Gilchrist MD3,
  5. Lora Bram MS4,
  6. E. Barry Greenberg MD4,
  7. John D. Wegenke MD4,
  8. Laura Stephenson BS5,
  9. Jason Gee MD4,
  10. Changyong Feng PhD6

Article first published online: 6 OCT 2006

DOI: 10.1002/cncr.22224

Issue

Cancer

Cancer

Volume 107, Issue 9, pages 2173–2179, 1 November 2006

Additional Information

How to Cite

Messing, E. M., Madeb, R., Young, T., Gilchrist, K. W., Bram, L., Greenberg, E. B., Wegenke, J. D., Stephenson, L., Gee, J. and Feng, C. (2006), Long-term outcome of hematuria home screening for bladder cancer in men. Cancer, 107: 2173–2179. doi: 10.1002/cncr.22224

Author Information

  1. 1

    Department of Urology, University of Rochester, Rochester, New York

  2. 2

    Department of Preventative Medicine, University of Wisconsin at Madison, Madison, Wisconsin

  3. 3

    Department of Pathology, University of Wisconsin at Madison, Madison, Wisconsin

  4. 4

    Department of Surgery, University of Wisconsin at Madison, Madison, Wisconsin

  5. 5

    Wisconsin Cancer Reporting System, Madison, Wisconsin

  6. 6

    Department of Biostatistics, University of Rochester, Rochester, New York

  1. †

    Fax: (585) 442-8350

*Department of Urology, University of Rochester, 601 Elmwood Avenue, Box 656, Rochester, NY 14642

Publication History

  1. Issue published online: 24 OCT 2006
  2. Article first published online: 6 OCT 2006
  3. Manuscript Accepted: 28 JUL 2006
  4. Manuscript Revised: 25 JUL 2006
  5. Manuscript Received: 15 JUN 2006

Funded by

  • State of Wisconsin Division of Health
  • Department of Health and Social Services
  • Ashley Family Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (171K)

REFERENCES

  • 1
    Jemel A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55: 10–30.
    Direct Link:
  • 2
    Jewett HJ, Strong GH. Infiltrating carcinoma of the bladder: relation of depth of penetration of the bladder wall to incidence of local extension and metastases. J Urol. 1946; 55: 366–372.
  • 3
    Freeman JA, Esrig DE, Stein JP, et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer. 1995; 76: 833–839.
    Direct Link:
  • 4
    Messing EM. Urothelial tumors of the urinary tract. In: Walsh, PC, VaughanEDJr., RetikAB, WeinAJ, editors. Campbell's Urology.8th ed. Philadelphia: WB Saunders Company; 2002: 2732–2784.
  • 5
    Hopkins SC, Ford KS, Soloway MS. Invasive bladder cancer: support for screening. J Urol. 1983; 130: 61–64.
  • 6
    Kaye KW, Lange PH. Mode of presentation of invasive bladder cancer: reassessment of the problem. J Urol. 1982; 128: 31–33.
  • 7
    Vaidya A, Soloway M, Hawke C, et al. De novo muscle invasive bladder cancer: is there a change in trend? J Urol. 2001; 165: 47–50; discussion,50.
  • 8
    Messing EM. De novo muscle invasive bladder cancer: is there a change in trend? [editorial comment] J Urol. 2001; 165: 50.
  • 9
    Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol. 1993; 149: 749–752.
  • 10
    Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WFJr. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol. 1989; 141: 22–29.
  • 11
    Sarosdy MF, Lamm DL. Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol. 1989; 142: 719–722.
  • 12
    Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859–866.
  • 13
    Holmang S, Hedelin H, Anderstrom C, et al. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol. 1997; 157:800803; discussion, 804.
  • 14
    Jakse G, Loidl W, Seeber G, Hofstadter F. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J Urol. 1987; 137: 39–43.
  • 15
    Norming U, Tribukait B, Gustavsson H, Nyman CR, Wang NN, Wijkstrom H. Deoxyribonucleic acid profile on tumor progression in primary carcinoma in situ of the bladder: a study of 63 patients with Grade III lesions. J Urol. 1992; 147: 11–15.
  • 16
    Cookson MS, Sarosdy MF. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol. 1992; 148: 797–801.
  • 17
    Prout GRJr., Barton BA, Griffin PP, Friedell GH. Treated history of noninvasive grade 1 transitional cell carcinoma.The National Bladder Cancer Group. J Urol. 1992; 148: 1413–1419.
  • 18
    Marshall VF. Current clinical problems regarding bladder tumors. Cancer. 1956; 9: 543–550.
    Direct Link:
  • 19
    Ressequie LJ, Nobrega FT, Farrow GM, Timmons JW, Worobec TG. Epidemiology of renal and ureteral cancer in Rochester, Minnesota, 1950–1974, with special reference to clinical and pathologic features. Mayo Clin Proc. 1978; 53: 503–510.
  • 20
    Kishi K, Hirota T, Matsumoto K, Kakizoe T, Murase T, Fujita J. Carcinoma of the bladder: a clinical and pathological analysis of 87 autopsy cases. J Urol. 1981; 125: 36–39.
  • 21
    Oldbring J, Hellsten S, Lindholm K, Mikulowski P, Tribukait B. Flow DNA analysis in the characterization of carcinoma of the renal pelvis and ureter. Cancer. 1989; 64: 2141–2145.
    Direct Link:
  • 22
    O'Donnell MA, Lilli K, Leopold C. Contemporary profile of superficial bladder cancer as revealed from an open-entry national multicenter study. J Urol. 2004; 171: 75a.
  • 23
    Messing EM, Young TB, Hunt VB, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology. 1995; 45: 387–396; discussion,396–397.
  • 24
    Messing EM, Reznikoff CA. Normal and malignant human urothelium: in vitro effects of epidermal growth factor. Cancer Res. 1987; 47: 2230–2235.
  • 25
    Messing EM, Young TB, Hunt VB, Rust P, Wehbie JM. Urinary tract cancers found by home screening with hematuria dipsticks in healthy men over 50 years of age. Cancer. 1989; 64: 2361–2367.
    Direct Link:
  • 26
    Messing EM, Young TB, Hunt VB, et al. Home screening for hematuria: results of a multiclinic study. J Urol. 1992; 148: 289–292.
  • 27
    Messing EM, Young TB, Hunt VB, et al. Hematuria home screening: repeat testing results. J Urol. 1995; 154: 57–61.
  • 28
    American Joint Committee for Cancer Staging and End-Results Reporting. Manual for Staging of Cancer, 1978. Chicago: Whiting, 1978.
  • 29
    Center for Health Statistics, State of Wisconsin Department of Health and Social Services. Wisconsin Behavioral Risk Factor Survey. Madison: Center for Health Statistics, State of Wisconsin Department of Health and Social Services, 1992.
  • 30
    Lynch CF, Platz CE, Jones MP, Gazzaniga JM. Cancer registry problems in classifying bladder cancer. J Natl Cancer Inst. 1991; 83: 429–433.
  • 31
    Messing EM. Interstitial cystitis and related syndromes. In: WalshPC, RetikAB, StameyTA, VaughanED, editors. Campbell's Urology. 6th ed. Philadelphia: WB Saunders Company; 1992: 982–1005.
  • 32
    Cheng L, Neumann RM, Weave AL, et al. New proposal for subclassification of T1 bladder carcinoma [abstract]. J Urol. 2000; 163( Suppl): 1125A.
  • 33
    Younes M, Sussman J, True LD. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer. 1990; 66: 543–548.
    Direct Link:
  • 34
    Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991; 325: 1205–1209.
  • 35
    Vieweg J, Whitmore WFJr, Herr HW, et al. Thorough pelvic lymphadenectomy and radical cystectomy of lymph node positive bladder cancer. The Memorial Sloan-Kettering Cancer Center experience. Cancer. 1994; 73: 3020–3028.
    Direct Link:
  • 36
    Thorstenson A, Larson P, Wijkstrom H, et al. Bladder cancer characteristics in a population based study of newly detected tumours [abstract]. J Urol. 2003; 169: 8664A.
  • 37
    National Center for Health Statistics. U.S. Decennial Life Tables for 1989–1991, vol II. State life tables no. 50, Wisconsin. Hyattsville: National Center for Health Statistics, 1998.
  • 38
    Hayes RB, Friedell GH, Zahm SH, Cole P. Are the known bladder cancer risk-factors associated with more advanced bladder cancer? Cancer Causes Control. 1993; 4: 157–162.
  • 39
    Wisconsin Cancer Reporting System. Cancer in Wisconsin-1993. Madison: Wisconsin Department of Health and Social Services, 1993.
  • 40
    Madeb R, Messing EM. Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol. 2004; 22: 86–92.
  • 41
    Briggs NC, Young TB, Gilchrist KW, Vaillancourt AM, Messing EM. Age as a predictor of an aggressive clinical course for superficial bladder cancer in men. Cancer. 1992; 69: 1445–1451.
    Direct Link:
  • 42
    Britton JP, Dowell AC, Whelan P. Dipstick hematuria and bladder cancer in men over 60: results of a community study. BMJ. 1989; 299: 1010–1012.
  • 43
    Britton JP, Dowell AC, Whelan P, Harris CM. A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol. 1992; 148: 788–790.
  • 44
    Kim ED, Ignatoff JM. Unsuspected bladder carcinoma in patients undergoing radical prostatectomy. J Urol. 1994; 152: 397–400.
  • 45
    Bruskewitz RC. Veterans Administration randomized benign prostatic hypertrophy study. J Urol. 1992; 147(Part 2): 107A.
  • 46
    Fisher M. Use and Analysis of Data—an Evaluation of the Wisconsin Cancer Reporting System's Completeness of Case Reporting. Madison: Wisconsin Department of Health and Social Services, 1982.
  • 47
    Boman H, Hedelin H, Holmang S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol. 2002; 167: 80–83.
View Full Article (HTML) Get PDF (171K)